Background. The Expected Value of Sample Information (EVSI) is used to calculate the economic value of a new research strategy. Although this value would be important to both researchers and funders, there are very few practical applications of the EVSI. This is due to computational difficulties associated with calculating the EVSI in practical health economic models using nested simulations. Methods. We present an approximation method for the EVSI that is framed in a Bayesian setting and is based on estimating the distribution of the posterior mean of the incremental net benefit across all possible future samples, known as the distribution of the preposterior mean. Specifically, this distribution is estimated using moment matching coupled with simulations that are available for probabilistic sensitivity analysis, which is typically mandatory in health economic evaluations. Results. This novel approximation method is applied to a health economic model that has previously been used to assess the performance of other EVSI estimators and accurately estimates the EVSI. The computational time for this method is competitive with other methods. Conclusion. We have developed a new calculation method for the EVSI which is computationally efficient and accurate. Limitations. This novel method relies on some additional simulation so can be expensive in models with a large computational cost.
would, however, have been deemed cost-effective given the current knowledge about the underlying model inputs.
Despite the obvious benefits of calculating the EVSI, especially in terms of efficiently using research and development budgets, practical applications of EVSI calculations are scarce. 12 Initially, this was because the published approaches to calculating the EVSI were based on computationally intensive, nested Monte Carlo (MC) procedures. 13 Some older methods avoid the need for a nested simulation by assuming certain model conditions, such as independence in the model parameters and linearity, 6 which reduced the computation time but limited the applicability of these methods.
EVSI research has been active more recently, and this has led to the proposal of several alternative calculation methods. Some of these more recent methods calculate the EVSI for specific designs, such as cluster randomized clinical trials, 6, 14, 15 whereas others use approximations to avoid using nested simulations. [16] [17] [18] The most recent approaches have been developed to avoid rerunning the economic model, which means that the EVSI can be calculated using the samples that have already been obtained to perform the-often mandatory-probabilistic sensitivity analysis (PSA). 19, 20 These methods may be suitable in certain situations, especially in settings where each model run requires a large amount of computational time. However, they either require the specification of sufficient statistics or a large number of matrix calculations.
In this paper, we present a new computation method for the EVSI that can be used irrespective of the underlying structure in the health economic model. The method is based on determining the properties of a specific function of the net benefit. We suggest an approximation based on these properties and then demonstrate how this can be used to calculate the EVSI. Specifically, the approximation reuses PSA samples from the underlying model alongside a small number of estimates of the variance of the incremental net benefit obtained by rerunning the model. Therefore, this method relies on around 30 nested simulations compared to at least 600 21 for a standard EVSI analysis.
In models with a relatively short run time, our method has a similar computational cost to more recent alternatives. It is also simple to implement for virtually all model structures and realistic trial designs, possibly accounting for missingness or problems with follow-up, as it relies simply on Bayesian updating and variance calculations. Most importantly, the required Bayesian updating is in the same form as the analysis that would be required once the data are collected, which aligns the model used to plan the study with the one used for the actual data analysis. This is not always the case with traditional methods, when sample size calculations are based on simplistic approximations and analytic formulae.
The presentation of our method begins with the introduction of notation and other key concepts. The estimation method is then presented and it is implemented for an example from Ades et al. 6 Finally, we conclude with a discussion of the computational burden of this method and how this compares with other methods. This allows for the recommendation of when this new tool may be more suitable than the alternatives.
Notation And Concepts
The EVSI is calculated as the difference between the value of the decision made under the current level of uncertainty and the expected value of the decision made with the additional information obtained from the future trial. To present both the EVSI and our method more formally, we begin by introducing some notation and key concepts. First, we assume that the health economic model is defined using a set of parameters, denoted u. To perform probabilistic sensitivity analysis (PSA), the current level of uncertainty in these parameters, based on literature reviews, clinical trials or meta analyses, is defined using a probability distribution pðuÞ. 22 To calculate the EVSI, it is assumed that T treatments are under consideration. To compare these treatments, we define the net benefit of each treatment t = 1; . . . ; T based on these model parameters, which we indicate as NB u t . Strictly speaking, we assume that NB u t does not reflect individual level uncertainty; so, if all the u values were known with certainty, then NB u t would be a fixed number. The value of the best decision under current information is the treatment with the maximum net benefit value:
The EVSI is concerned with a trial in which we gain ''more information'' by gathering a new dataset X. This new dataset is what we would collect in the future trial; for example, the number of patients responding to a treatment or the number of false-positive test results. These data are useful as they provide us with more information about the underlying model parameters, which, in turn, influence the decision. Specifically, if the future trial had already been undertaken and the data observed as x, the optimal decision conditional on that observed sample would be
where the expectation of the net benefit is taken over the distribution of the parameters conditional on the information in the sample x. However, as new research has not been carried out yet and the data X have not been observed, the EVSI is calculated by averaging over all possible future datasets to give the average value of the decision made with the additional information contained in the sample;
In general, the distribution of all possible future samples is defined using the same distribution that would be used to model the data if it had been observed. 19, 20 Formally, this means that the distribution of X is defined through its relationship with u; this allows us to sample values from the distribution of pðXÞ, as we will see below.
The analysis required for the EVSI is exactly the analysis that would be required if the statistical modelling underpinning the health economic model was inferred using Bayesian methods. In this setting, the PSA distributions for the parameters would be called the prior for u, and this prior is combined with the data X to update the information about the model parameters and determine a posterior distribution for the parameters u conditional on the data X. In fact, in Bayesian analysis, the inner expectation in the first term of equation (1) is known as the preposterior mean; i.e., the posterior mean before the data have been collected. The preposterior mean, which we will denote m X t , is the key element in the EVSI calculation and it is also the term that makes the EVSI computationally expensive, as it has traditionally been estimated by simulation. In the most general setting, this requires posterior updating, usually with Markov Chain Monte Carlo (MCMC) methods, which are very computationally intensive.
Therefore, all the approximation methods 6,16,18-20 focus on estimating this preposterior mean without using full MCMC sampling. Our approximation reuses the information contained in NB u t to estimate the preposterior mean or, more specifically, the distribution of the preposterior mean. The concept of ''distribution of a mean'' is rather counterintuitive in a standard statistical analysis. However, it makes sense in this context, because we are interested in the posterior before the data have been collected. This implies that there is uncertainty as to which of all the possible future samples will occur were we to conduct the study. Each possible sample would yield a different posterior mean and so the sampling distribution for the data induces a distribution over the posterior means. To make this more clear, we use a simple example, which is also used to highlight how NB u t can be used to approximate this distribution.
The Distribution of the Preposterior Mean -An Example
Suppose that a new drug is available and is associated with a probability u of curing a particular disease. As this drug is new, we assume that there is very limited evidence on its effectiveness. This could be expressed, in a very simplistic way, by assuming that all values for u, between 0 and 1, are equally likely. Mathematically, this is equivalent to modelling u ; Uniform ð0; 1Þ. Of course, in practical settings, it is likely that information about the effectiveness of the treatment is available and this could be easily included by using an alternative distribution for pðuÞ.
In this simple model, the treatment is effective if the disease has been cured and the drug costs are known to be equal to c. As we are only interested in population level effectiveness, the effectiveness of the treatment is the probability of a cure u. We finally assume that the decision maker is prepared to pay k monetary units for each person that is cured of the disease.
To simplify this example further, the new treatment is being compared with the current standard of care, which is to leave the disease untreated. This option has no cost but also has no effectiveness, as this (non-life-threatening) disease does not improve without drug intervention. Thus, the 2 net benefit values are NB u 1 = 0 and NB u 2 = ku À c:
The trial involves giving N people the drug and observing how many are cured. This means that the sampling variability can be characterized using a Binomial distribution X ju ; Binomial ðN ; uÞ; with u the probability of being cured. The distribution pðX juÞ and the prior for u can then be combined to give the predictive distribution of the future samples X as
This calculation implies that, if we begin by assuming that all values for u are equally likely, then all values of the future sample are equally likely. This is because the possible values for X , the number of people cured, are 0; 1; . . . ; N and each of them has probability 1 N + 1 . Once the distribution for the possible data values is known, the distribution of the preposterior mean is found by calculating the posterior mean for both the net benefit functions. As NB u 1 does not depend on u, the posterior mean for NB u 1 is m X 1 = 0. Therefore, the preposterior mean for NB u 1 does not have a distribution in this example and is just equal to 0. However, the posterior mean for NB u 2 does depend on the future sample X :
as the second integral is exactly the mean of ujX and it can be shown that ujX ; Betað1 + X ; 1 + N Þ. Therefore, the distribution of m X 2 is directly related to the distribution of X , which assumes that all values for X are equally likely and thus all values of m X 2 are equally likely. However, this belief for X is a direct result of our initial beliefs that all values of u are equally likely. In this sense, the distribution of the preposterior mean is strongly linked to our initial beliefs about u, which are encoded in our prior distribution. The Appendix presents 2 alternative models to demonstrate that the prior distribution for u is similar to the distribution of the preposterior mean, in many settings.
Estimating the Distribution of the Preposterior Mean
Historically, EVSI calculations have been carried out by estimating the distribution of the preposterior mean by Monte Carlo simulation 6, 13, 23 or by approximating the relationship between the samples X and the posterior mean. 6, 20 However, we have just demonstrated that the distribution of the preposterior mean for the net benefit, which we will indicate with pðm X t Þ, is related to the prior for the model parameters. More importantly, in health economic evaluations, PSA samples from the prior are already available when the EVSI is being calculated. 22, 24, 25 Therefore, these PSA samples can be used to save computational time when estimating pðm X t Þ. (Menzies 19 also uses the similarity between the PSA samples for the net benefit and the distribution of the preposterior mean as a basis for his method but the proposed transformations differ significantly.) Specifically, our method estimates pðm X t Þ using the PSA samples and additional knowledge about the mean and variance of the preposterior mean, which are both estimated by simulation.
Expectation and Variance for the Preposterior Mean
To estimate the mean and variance of m X t , we use formulae for conditional iterated expectation. 26 Firstly, this implies that the mean of m X t is given by
i.e., the average of the preposterior mean is equal to the mean of the NB u t , which can be obtained using the PSA samples for the net benefit. This implies that performing the EVSI analysis-i.e., considering the possible values of a future data set before obtaining data-cannot give any additional information or change our current decision, as, on average, the optimal decision would remain the same. To actually change the optimal decision the research must be carried out.
Secondly, the variance of the preposterior mean is given by
In other words, the variance of the preposterior mean is equal to the variance of the net benefit minus the average posterior variance, over all possible future samples. Therefore, to calculate the mean and variance of the preposterior mean by simulation, we only need to estimate the average posterior variance over all possible samples X, as long as the PSA samples have already been obtained. Most importantly, the section headed, ''Estimating the expected variance of the posterior net benefit'' below will demonstrate that a suitable estimate of the expected posterior variance can be obtained using only a small number of simulated future samples. This significantly reduces the number of samples required to calculate the EVSI as compared with standard simulation-based methods.
Moment Matching
Assuming that the mean and variance of the preposterior mean have been estimated, p m X t À Á can be approximated using moment matching. 27, 28 In general, this involves approximating p m X t À Á by taking a known distribution and ensuring that the mean and variance of this distribution equal the mean and variance of p m X t À Á
. For example, this moment matching method could involve approximating the distribution of the preposterior mean by a Normal distribution with the correct mean and variance.
However, this strategy is unlikely to give accurate estimates, as the EVSI is strongly influenced by the tails of the distribution of the preposterior mean because this is where the optimal decision is most likely to change. Therefore, the EVSI estimate will be significantly improved if the distribution of the preposterior mean is approximated by moment matching with the PSA samples for NB u t . As these samples represent our initial beliefs about the net benefit of each treatment and, as seen earlier in this section in the example of the distribution of the preposterior mean, our initial beliefs have a strong impact on the shape of pðm X t Þ.
Linear Transformation to Moment Match. In practice, we suggest that a linear transformation of the NB u t should be used to estimate the distribution of the preposterior mean by moment matching. This involves estimating the constants a and b such that a NB u t + b has the same mean and variance as pðm X t Þ:
where s 2 is the variance of the preposterior mean, calculated as the difference between the variance of the net benefit and the expected posterior variance. Solving for a and b yields
which depend on the expectation and variance of the net benefit and its expected posterior variance. Interestingly, these constants allow for a relatively simple interpretation of the approximation of p m X t À Á . The constant a is related to the reduction in the net benefit variance that will be obtained by learning X. This means that the more information X contains about the net benefit, the higher the value of a. In some ways, we can think of this as the amount of variance that is ''explained'' by the fact that we have not yet observed X.
The constant b is then the mean of the preposterior distribution weighted by one minus this explained variance, where the weight is related to how much information is contained in X. Thus, the density of the preposterior mean is estimated as a convex combination of our initial beliefs about the net benefit and the mean of the net benefit (which is also the mean of the preposterior distribution).
In general, the higher the sample size of X, the more information it contains and therefore the higher the value of a. This implies that, as the sample size in the data collection exercise increases, our approximation for pðm X t Þ approaches the PSA samples for the net benefit; i.e., an infinite future sample implies that the distribution of the preposterior mean is exactly equal to our initial beliefs about the net benefit. We explore this slightly counterintuitive result in detail in the Appendix along with further motivation for our moment matching method. Note that, as a rule of thumb, the approximation is most accurate when the sample size of the future dataset is greater than 20, especially when the data are discrete, as seen in the earlier example of the distribution of the preposterior mean.
As PSA simulations for the net benefit are generally available as a component of a full economic analysis, 22, 24, 25 these samples can be used to estimate the mean and variance of NB u t . These mean and variance values can then be used to calculate a and b. Additionally, the PSA simulations can be rescaled using these constants so the only additional element required to approximate the distribution of the preposterior mean is an estimate of the expected variance of the posterior net benefit across different possible future samples X.
Estimating the Expected Variance of the Posterior Net Benefit
We suggest that the expected variance of the posterior net benefit should be estimated by simulation. While this seems computationally intensive, the number of simulations can be kept fairly low as the posterior variance is relatively stable across different future samples X, meaning that the variance does not change substantially for different samples. This stability is most extreme when the data distribution and our initial beliefs are both normal. In this case, the posterior variance is the same irrespective of the posterior mean, as it is only related to the variance of the sample X and the sample size.
In non-normal settings (e.g., involving the collection of data for costs or utility measures), the posterior variance is no longer unrelated to the mean of the sample X.
However, as demonstrated in the Appendix, a small number of ''posterior'' samples (around 20 to 50) can be used to estimate the expected posterior variance accurately, even in highly non-normal settings. Crucially, this result is dependent on intelligently choosing which posterior samples to use.
Specifically, we need to calculate the expected posterior variance:
where the 2 outer expectations on the right hand side estimate the expectation over all possible values of X. In general, we need to choose a small number of u values whilst ensuring that the full range of u values is explored before sampling one future sample conditional on each value of u. This estimates the expected posterior variance accurately using quadrature. 29 In most health economic models, u contains a large number of parameters, sometimes upwards of 1,000. 30 However, most trials are only designed to gather information about a small number of these parameters (in fact, trials often focus on a single primary outcome to be estimated reliably). We denote these targeted parameters f and it is only these parameters that we must explore intelligently to estimate the expected posterior variance. Specifically, it is suggested that Q evenly spaced values for f should be chosen from the PSA samples for f. These Q values are then used to simulate one future sample from Xjf for each f value, resulting in Q simulated datasets.
A posterior distribution is then found for each simulated future sample. This gives Q posterior distributions, which will usually be found using MCMC simulation through computer programs such as BUGS, 31 JAGS, 32 or Stan. 33 For each posterior distribution, we then need to calculate the variance of the net benefit to approximate the EVSI using moment matching. In general, Q should be greater than 20 to obtain sufficiently accurate estimates of the variance. However, as Q increases, the EVSI estimate becomes more accurate; although, this is at the cost of longer computational time. Estimating the variance in this manner implies that our method can be used irrespective of the underlying model structure, provided it is computationally feasible to find the posterior distribution by MCMC simulation Q times.
Calculating the EVSI for a Specific Set of Treatment Options
To calculate the EVSI using this estimated distribution of the preposterior mean, it is necessary to determine the joint distribution of the preposterior mean net benefit across all the different treatment options. Theoretically, this adds little complication to the method already described, in that a posterior variance-covariance matrix for all the net benefits must be estimated, instead of a scalar variance.
However, the EVSI estimate is more stable computationally if the incremental net benefit (INB) of treatment r versus treatment s, defined as INB u = NB u r À NB u s , is used instead. In this case, the optimal treatment, under current or future information, is found by comparing the INB with 0. For example, if only 2 treatment options are considered, then treatment t = 2 is optimal if the INB is positive while t = 1 is optimal if it is negative. More importantly, if the distribution of the preposterior mean of the INB is estimated using the moment matching method, the EVSI is computed as
where m X = E ujX INB u Â Ã and the mean and variance of the INB are scalars rather than matrices.
When more than 2 treatment options are being compared, working with the INB reduces the size of the posterior variance-covariance matrix that must be estimated, leading to greater numerical stability. For example, if 3 treatment options are considered, using the INB implies that only 3 unique elements must be estimated in the posterior variance-covariance matrix rather than 6.
Nuisance Parameters
Finally, an extension to the method presented so far is needed to reflect that the new research only informs a small subset of the model parameters f, as discussed in the section estimating the expected variance of the posterior net benefit. In general, it is unlikely that the distribution for INB u , conditional on all the underlying model parameters u, will be the same as the distribution of the preposterior mean for data informing f. Therefore, it is necessary to determine the distribution of the INB conditional solely on f, indicated as INB f . It is then these samples of INB f that are rescaled linearly to moment match with the distribution of the preposterior mean.
To demonstrate the difference between INB u and INB f , we consider a simple 2 parameter model where: f ; Betað1; 4Þ, c ; NormalðÀ0:5; 1Þ, NB u 0 = 10000cÀ 4000; NB u 1 = 10000f À 6 500; and INB u = 10000ðfÀ cÞ À 2500. Figure 1 shows that the prior for INB u is approximately normal-particularly in the tails-whereas, as the INB is linear in f, the distribution of INB f is a shifted and scaled Beta distribution, which is non-normal. Therefore, if INB u was used to approximate the distribution of the preposterior mean for new research that only informs the parameter f, then the shape of that approximate distribution would be incorrect, leading to inaccurate estimates for the EVSI.
To identify a more appropriate shape for the distribution of the preposterior mean in the presence of nuisance parameters, i.e. the parameters c such that u = ðf; cÞ, the uncertainty due to c should be marginalized out by calculating:
Whereas calculating this expectation can be computationally intensive, it should be estimated before proceeding to calculate the EVSI. 34 This is because calculating the EVSI requires a study design for the future research, which is time consuming to determine for a realistic trial.
Therefore, before designing the trial, the value of resolving all the uncertainty in f should be calculated. This is known as the expected value of partial perfect information (EVPPI) and is based on the expectation in (3 35 or Heath et al. 36 offer computationally efficient procedures for estimating this expectation using nonparametric regression, with code available in the R package bcea 37 or as a stand-alone function. 38 Finally, to rescale the sample of the INB f , rather than INB u , the constant a from section titled ''Estimating the distribution of the preposterior mean'' becomes:
where s is the variance of the preposterior mean. Note that s must still be calculated as a function of the Case Study: Ades et al. 6 Decision Tree Model
To demonstrate the effectiveness of our methodology, we used a decision tree model developed in Ades et al. 6 This model has 2 treatment options, a standard of care and a new treatment, aimed at avoiding a critical event. This critical event leads to a reduction in QALYs for the remainder of the patient's life. The new treatment reduces the probability of the critical event but the patient may also experience side effects, which give a short-term reduction in QALYs along with a direct cost of additional treatment. The model has 11 parameters, of which 4 are subject to uncertainty, which is then modelled using 4 mutually independent distributions; a complete model description is given in Ades et al. 6 or Strong et al. 20 For this case study, we consider 4 different data collection exercises, the first 3 have been tackled by Ades et al. 6 and the fourth investigates the moment matching method when f is not unidimensional:
1. To reduce uncertainty in the probability of side effects for the new treatment f 1 , 60 patients are given the new treatment and the number who suffer from side effects is recorded. 2. To reduce uncertainty in the quality of life after the critical event f 2 , the quality of life for 100 patients who experienced the event is recorded. 3. To reduce uncertainty in the odds ratio of the effectiveness of the 2 treatments f 3 , a randomized control trial with 200 patients on each arm is undertaken. 4. To reduce uncertainty in the probability of the critical events in both treatment arms f C 3 ; f T 3 , the same randomized control trial is undertaken but the analysis informs these 2 probabilities directly.
For a full description of the distributional assumptions for these studies, particularly the difference between study 3 and study 4, see Strong et al. 20 
Computations
To calculate the EVSI using the moment matching methodology, 1 million simulations were taken for the 4 stochastic model parameters. These were then combined with the other 7 parameters to calculate 1 million simulations for the INB under current information. These simulations for INB u were used to find INB f using GAM regression 39 obtained with the gam function from the mgcv package 40 in R. The simulations were also used to find the mean and variance of INB u .
To estimate the preposterior variance, the expected posterior variance was estimated using MCMC procedures with Q, the number of f values, equal to 30. This was achieved using JAGS through R 41 with 10,000 simulations from each posterior distribution and 1,000 simulations used as burn-in. This means that in total 1,330,000 simulations were used to estimate the EVSI in this example; although, note that the PSA simulations were reused for each EVSI calculation. Fewer simulations could be used but, as this example has a small computational cost, it was possible to use this number of simulations to improve the accuracy of the methods. The computational time required to estimate the posterior variance with this number of simulations was between 3.8 and 6.1 s.
To assess the accuracy of our method, the expected posterior variance was estimated using the above procedure 1,000 times for each trial. Each of these estimates for the expected posterior variance was then used to approximate the EVSI using moment matching to give a distribution for the EVSI estimate obtained. In a standard analysis, therefore, our method would produce a point estimate for the EVSI rather than the distributions given in the example outlined in the previous section.
To determine the accuracy of our method, we compared with the computationally intensive 2-step nested Monte Carlo procedure 13 and the Strong et al. 20 method based on sufficient statistics and non-parametric regression, which is an accurate and efficient estimation method for models where the data can be summarized using a low-dimensional sufficient statistic. For the experiments targeting f 1 , f 2 and f 3 , the comparator values are taken directly from the Strong et al. paper, where the estimates are based on 10 10 and 10 6 simulations, respectively. For the 2 parameter EVSI estimate, the results for these 2 methods were obtained using the same number of simulations with the code given in the Appendix. The computational times to obtain these estimates were 8 Figure 2 plots the sampling distribution of the EVSI estimate, over the different estimates of the expected posterior variance, obtained using our moment matching method for the 4 alternative study designs. The solid line gives the value of the estimate obtained by nested Monte Carlo (which can be considered as the ''truth''), the dashed line is the estimate obtained using the Strong et al. 6 method, and the dotted line is the average moment matching estimate. Evidently, the moment matching method is in line with these 2 alternative estimation methods for the studies considered; although, the 2-parameter estimation has a slight upward bias. Nonetheless, the true EVSI value is well within the 90% interval, represented by the solid black line on the axis in Figure 2 . Figure 2 also demonstrates that the EVSI estimate calculated using moment matching is less accurate for experiments with smaller EVSI: as the EVSI gets smaller, the 90% intervals get wider. This is because the estimate is based on the difference between the prior variance and the expected posterior variance. When the EVSI is small, then this difference is also small; therefore, the posterior and prior variances need to be estimated with greater precision because the difference can be greatly affected by the Monte Carlo error in the variance estimation. It is important to note that the accuracy demonstrated in Figure 2 depends on accurately estimating the prior variance. Therefore, our moment matching method should not be used if the initial PSA simulation size is very small. 
Results

Discussion
We have presented an estimation method that reduces the significant computational burden required to accurately estimate the EVSI. This method is based on using information already available to the researcher, typically in the form of PSA simulations, a relationship that is also exploited by Menzies 19 despite large differences between the 2 methods. Our method involves moment matching, performing a linear transformation of the PSA simulations for the incremental net benefit. To perform this matching, nested sampling is used to calculate the expected posterior variance across different samples. For the example in this paper, the required number of nested simulations was reduced from 10 6 to 30, offering a significant computational saving especially in more complex models where running the model has a computational cost.
When Should This Method be Used?
Several methods have been proposed for estimating the EVSI. A large number of these are restricted to models that fulfil certain conditions, either on the use of th eeconomic model or the structure of the data, or potentially both. 6, 14, 15, 18 The moment matching method is likely to have a higher computational cost than these methods but can be used in any setting. Current general-purpose methods, i.e., those that can be used irrespective of the underlying model, include the one presented by Strong et al., used as a comparator in this paper, the one developed by Menzies, 19 and a method based on Laplace approximations to bypass the use of MCMC to perform the Bayesian updating. 16, 17 Firstly, provided a low-dimensional sufficient statistic is available to capture all the information contained in the sample, the Strong et al. 20 method typically outperforms the other methods in terms of computational time. However, it may be challenging to determine an appropriate sufficient statistic, particularly for complex designs. The Menzies 19 method also avoids the need for additional model runs but does involve a large number of matrix operations, which has a significant computational cost when the number of PSA simulations is large. Therefore, the moment matching method can be significantly faster than this alternative when the model itself has a relatively small computational cost. Conversely, if the underlying health economic model is computationally intensive to run, it would not be feasible to rerun the model a large number of times and the Menzies method could be used.
Finally, using Laplace approximations requires T ð2p + 1Þ model evaluations, where p is the number of model parameters and T is the number of treatment options. 16 It also involves numerical optimization, which has an associated computational cost. Nonetheless, this method could be more efficient than our moment matching method in health economic models with a small number of underlying parameters but a long run time.
In conclusion, the moment matching method presented in this paper is a computationally efficient method for estimating the EVSI and is most helpful in cases where a sufficient statistic for the data is difficult to specify but the computational time taken to run the model itself is relatively small; although, it can be competitive in terms of computational time for simple models. Therefore, we believe this method is an important addition to EVSI literature, as it is based solely on Bayesian updating, which typically must be designed in order to analyse the data once the experiment has been performed. If the research goes ahead, the calculation of the EVSI will aid in modelling trial results as researchers can use the procedure that has already been defined.
